Cidara Therapeutics, INC 8-K filings

Cidara Therapeutics, Inc. has completed its merger with Merck Sharp & Dohme LLC, becoming a wholly-owned subsidiary.

Merck will acquire Cidara Therapeutics for $221.50 per common share, totaling approximately $9.2 billion, to expand its respiratory portfolio with late-phase antiviral agent CD388.

Cidara Therapeutics reported its third quarter 2025 financial results and provided a corporate update, highlighting an expanded and accelerated Phase 3 plan for its influenza preventative therapeutic, CD388.

Cidara Therapeutics entered a BARDA agreement for up to $339.2 million to advance manufacturing and clinical development of its non-vaccine influenza preventative therapeutic, CD388.

Cidara Therapeutics announced an accelerated and expanded Phase 3 trial for its influenza prophylactic CD388, significantly increasing the potential patient population.

Cidara Therapeutics announced positive Phase 2b trial results for its influenza preventative CD388, significantly strengthening its balance sheet with a $402.5 million public offering.

Cidara Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 7,954,546 shares of common stock at $44.00 per share, expecting to raise approximately $350.0 million in gross proceeds.

Cidara Therapeutics, Inc. announced the suspension and termination of its at-the-market (ATM) common stock offering prospectus with Jefferies LLC, effective June 24, 2025.

Cidara Therapeutics, Inc. announced positive topline results from its Phase 2b NAVIGATE trial, demonstrating that its investigational drug CD388 significantly prevented seasonal influenza in healthy unvaccinated adults.

Cidara Therapeutics, Inc. announced stockholder approval to significantly increase its authorized common stock to 100 million shares and expand its 2024 Equity Incentive Plan, enhancing its capacity for future equity-based compensation and corporate flexibility.

Cidara Therapeutics reported its Q1 2025 financial results, highlighted by progress in the Phase 2b NAVIGATE trial for CD388 and key personnel promotions.

Cidara Therapeutics announces completion of Phase 2b NAVIGATE trial enrollment, potential early efficacy analysis, and a $105 million private placement, alongside its Q4 and full year 2024 financial results.

Cidara Therapeutics announces the departure of CFO Preetam Shah and the appointment of Frank Karbe as the new CFO, effective February 24, 2025.

Cidara Therapeutics has announced the resignation of a board member, the departure of its Chief Medical Officer, and the appointment of a new director, along with changes to director compensation.

Cidara Therapeutics has successfully raised $105 million through a private placement, led by Venrock Healthcare Capital Partners, to fund its research and development efforts.

Cidara Therapeutics announced its third quarter 2024 financial results, highlighted by the initiation of a Phase 2b trial for its influenza drug candidate CD388 and a corporate restructuring.

Cidara Therapeutics has commenced its Phase 2b NAVIGATE trial, evaluating CD388 as a pre-exposure prophylaxis for influenza.

Cidara Therapeutics is reducing its workforce by 30% to focus on the clinical development of its influenza product candidate, CD388.

Cidara Therapeutics reacquired global rights to CD388, closed a $240 million private placement, divested rezafungin, and reported a net loss of $91.2 million for the second quarter of 2024.

Cidara Therapeutics' stockholders approved an increase in authorized common stock shares and a new equity incentive plan at their 2024 Annual Meeting.

Cidara Therapeutics has announced the finalization of 2023 executive bonuses and provided a revised summary compensation table, including pay versus performance details.

Cidara Therapeutics reacquired its CD388 program, divested rezafungin, closed a $240 million private placement, and reported a net loss of $10.3 million for the first quarter of 2024.

Cidara Therapeutics is prioritizing its Cloudbreak platform, particularly CD388 for influenza prevention, after divesting rezafungin and securing a significant $240 million private placement.

Cidara Therapeutics has sold its rezafungin acetate assets to NAPP Pharmaceutical Group, including rights to future milestones and royalties.

Cidara Therapeutics has entered into a license agreement with Janssen, regaining full control of its influenza program, and secured $240 million through a private placement of convertible preferred stock.

Cidara Therapeutics has sold its rezafungin acetate assets to NAPP Pharmaceutical Group, including intellectual property, regulatory approvals, and future milestone and royalty rights.

Cidara Therapeutics reported its fourth quarter and full year 2023 financial results, highlighted by revenue from milestones and product sales, and announced a 1-for-20 reverse stock split effective April 23, 2024.

Cidara Therapeutics will restate its financial statements from 2021 to 2023 due to errors in accounting for indirect taxes, leading to an understatement of liabilities and operating expenses.

Cidara Therapeutics' stockholders approved a reverse stock split and a proposal to adjourn the special meeting if necessary to solicit additional proxies.

Cidara Therapeutics has been granted an extension by the Nasdaq Hearings Panel to regain compliance with the minimum bid price requirement by May 7, 2024.